Japanese company launches canine pancreatitis drug
Brenda is approved for use in Japan and at any early stage with U.S. regulators.
A manufacturer of industrial chemicals has earned Japanese approval of its first veterinary product, a treatment for acute pancreatitis in dogs, and is working to eventually deliver the drug to U.S. practitioners.
The company, Ishihara Sangyo Kaisha Ltd., reported Sept. 28 that the Japanese Ministry of Agriculture, Forestry and Fisheries approved Brenda (fuzapladib sodium hydrate) for the reduction of clinical signs associated with acute canine pancreatitis.
“Pancreatitis is often treated by addressing the symptoms,” said Hiroshi Shikama, general manager of research and development with Ishihara Sangyo Kaisha (ISK). “Brenda has a critical drug efficacy for acute pancreatitis, allowing for a speedier recovery and decreased likelihood of long-term damage.”
The U.S. Food and Drug Administration issued an Investigational New Animal Drug file number to ISK in support of further clinical studies of Brenda, the company stated.
Brenda, which ISK described as the first therapeutic drug for pancreatitis in dogs, will be distributed in Japan by Nippon Zenyaku Kogyo Co.
ISK is headquartered in Osaka, Japan.